**Supplementary Tables**

**Table S1** The correlation of CCL18 expression with clinicopathologic

characteristics of GC patients

|  |  |  |  |
| --- | --- | --- | --- |
| Variables | Cases(n) | CCL18 | *P* value |
|  High |  Low |
| Total | 265 | 212 | 53 |  |
| *Age (years)* |  |  |  |  |
| ≥60 | 180 | 149 | 31 |  |
| <60  | 85 | 63 | 22 | 0.103 |
| *Gender* |  |  |  |  |
| Male | 169 | 137 | 32 |  |
| Female  | 96 | 75 | 21 | 0.632 |
| *Pathological stage* |  |  |  |  |
|  Ⅰ/Ⅱ | 129 | 108 | 21 |  |
|  Ⅲ/Ⅳ | 136 | 104 | 32 | 0.167 |
| *T stage* |  |  |  |  |
|  T1/T2 | 72 | 59 | 13 |  |
|  T3/T4 | 193 | 153 | 40 | 0.731 |
| *N stage*  |  |  |  |  |
|  Negative | 86 | 69 | 17 |  |
|  Positive | 179 | 143 | 36 | 1.000 |
| *M stage*  |  |  |  |  |
|  Negative | 240 | 192 | 48 |  |
|  Positive | 25 | 20 | 5 | 1.000 |

**Table S2** The correlation of CCR8 expression with clinicopathologic

characteristics of GC patients

|  |  |  |  |
| --- | --- | --- | --- |
| Variables | Cases(n) | CCR8 | *P* value |
|  High |  Low |
| Total | 293 | 57 | 236 |  |
| *Age (years)* |  |  |  |  |
| ≥60 | 198 | 35 | 163 |  |
| <60  | 95 | 22 | 73 | 0.274 |
| *Gender* |  |  |  |  |
| Male | 183 | 35 | 148 |  |
| Female  | 110 | 22 | 88 | 0.880 |
| *Pathological stage* |  |  |  |  |
|  Ⅰ/Ⅱ | 140 | 24 | 116 |  |
|  Ⅲ/Ⅳ | 153 | 33 | 120 | 0.377 |
| *T stage* |  |  |  |  |
|  T1/T2 | 76 | 12 | 64 |  |
|  T3/T4 | 217 | 45 | 172 | 0.403 |
| *N stage*  |  |  |  |  |
|  Negative | 96 | 17 | 79 |  |
|  Positive | 197 | 40 | 157 | 0.640 |
| *M stage*  |  |  |  |  |
|  Negative | 266 | 52 | 214 |  |
|  Positive | 27 | 5 | 22 | 1.000 |

**Table S3** Cox regression analysis of CCR8 expression as survival predictor

|  |  |  |  |
| --- | --- | --- | --- |
|  Variables | Univariate Cox regression analysis |  | Multivariate Cox regression analysis |
| RR (95% CI) | *P* value |  | RR (95% CI) | *P* value |
| *Age (years)*  |  |  |  |  |  |
| ≥ 60 vs. < 60 | 1.689 (1.084 to 2.632) | 0.021 |  | 1.862 (1.193 to 2.904) | 0.006 |
| *Gender* |  |  |  |  |  |
| Male vs. Female  | 1.170 (0.777 to 1.761) | 0.453 |  | NA | NA |
| *Pathological stage* |  |  |  |  |  |
| Ⅲ/Ⅳ vs.Ⅰ/Ⅱ | 1.875 (1.242 to 2.833) | 0.003 |  | 1.343 (0.791 to 2.278) | 0.275 |
| *T stage*  |  |  |  |  |  |
| T3+T4 vs. T1+T2 | 1.588 (0.971 to 2.596) | 0.065 |  | NA | NA |
| *N staging*  |  |  |  |  |  |
| Positive vs. Negative  | 2.170 (1.331 to 3.539) | 0.002 |  | 1.845 (0.985 to 3.456) | 0.056 |
| *M stage*  |  |  |  |  |  |
| Positive vs. Negative  | 1.454 (0.795 to 2.658) | 0.224 |  | NA | NA |
| *CCR8 expression* |  |  |  |  |  |
| High vs. Low | 1.581 (1.013 to 2.469) | 0.034 |  | 1.549 (0.991 to 2.422) | 0.045 |

NA: not analyzed